- Home
- OTLY vs XFOR Comparison
OTLY vs XFOR Comparison
Compare OTLY & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLY | XFOR |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.2M | 323.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLY | XFOR |
|---|---|---|
| Price | $10.45 | $3.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $15.50 | ★ $28.50 |
| AVG Volume (30 Days) | 66.2K | ★ 735.9K |
| Earning Date | 02-11-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $842,996,000.00 | $33,979,000.00 |
| Revenue This Year | $4.69 | $1,266.01 |
| Revenue Next Year | $4.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.63 | ★ 2925.74 |
| 52 Week Low | $6.00 | $1.35 |
| 52 Week High | $18.84 | $24.43 |
Technical Indicators
Market Signals| Indicator | OTLY | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 43.87 |
| Support Level | $11.02 | $3.56 |
| Resistance Level | $11.64 | $4.24 |
| Average True Range (ATR) | 0.50 | 0.21 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 4.08 | 15.54 |
Price Performance
Historical ComparisonAbout OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.